BridgeMD
New treatment option for Brain Neoplasms
Official title CONNEctome-guided Navigation for Eloquent-area Tumor Surgery Trial
ClinicalTrials.gov ID: NCT07657403
What this study is testing
- What it's testing
- This study is designed for patients with brain tumors located in eloquent brain areas involved in language, motor, or major functional brain networks. The purpose of the study is to determine whether connectome-guided navigation-assisted microsurgical resection can better preserve neurological function after surgery than conventional tractography-guided surgery.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults
You may be able to join if
- Patients clinically diagnosed with brain tumors involving language areas, motor areas, or major functional brain networks, including the default mode...
- Karnofsky Performance Status (KPS) score of 70 or higher.
- Preoperative MRI demonstrating a spatial relationship between the tumor and major white matter tracts, such as the corticospinal tract or arcuate...
- No other neurological disease or underlying condition that may cause neurological dysfunction.
- No prior treatment for a brain tumor in the same region, such as radiotherapy.
You likely can't join if
- Pathologically or clinically suspected non-neoplastic brain lesion.
- Multifocal tumors.
- Incomplete evaluation data.
- Withdrawal from the study by the patient or legally authorized representative for any reason.
- Pregnancy, lactation, possibility of pregnancy, or planned pregnancy.
See the full eligibility criteria
- Patients clinically diagnosed with brain tumors involving language areas, motor areas, or major functional brain networks, including the default mode network, central executive network, dorsal attention network, or...
- Karnofsky Performance Status (KPS) score of 70 or higher.
- Preoperative MRI demonstrating a spatial relationship between the tumor and major white matter tracts, such as the corticospinal tract or arcuate fasciculus.
- No other neurological disease or underlying condition that may cause neurological dysfunction.
- No prior treatment for a brain tumor in the same region, such as radiotherapy.
- Tumor not extensively adherent to multiple critical network nodes.
- Planned craniotomy for tumor resection and provision of written informed consent by the patient or legally authorized representative.
- Pathologically or clinically suspected non-neoplastic brain lesion.
- Multifocal tumors.
- Incomplete evaluation data.
- Withdrawal from the study by the patient or legally authorized representative for any reason.
- Pregnancy, lactation, possibility of pregnancy, or planned pregnancy.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.